Pembrolizumab with Enzalutamide and androgen deprivation therapy for the treatment of metastatic hormone sensitive prostate cancer

Pembrolizumab in addition to enzalutamide and androgen deprivation therapy (ADT) is in clinical development for patients with prostate cancer which has spread from its original site (metastatic), and who are hormone sensitive (mHSPC). Prostate cancer is a cancer of the prostate gland (a small organ in a man’s pelvis) and is the most common cancer in men in the UK. The symptoms may vary depending on the stage of cancer but can include pain, tiredness, and problems emptying the bladder and the bowels. The metastatic form of prostate cancer is particularly dangerous and leads to a very poor prognosis hence additional treatment options are needed. The combination of pembrolizumab and enzalutamide with ADT could lead to increased anti-tumour activity, compared to either substance alone.